Ignite Creation Date:
2024-10-25 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06636409
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-10-02
Brief Title:
Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Liver transplantation is the primary intervention for decompensated chronic liver diseases and some cases of hepatocellular carcinoma This study aims to examine long-term mortality after liver transplantation and identify related risk factors in the modern immunosuppression era using a French multicenter cohort This study does not interfere with patients medical care The study method involves collecting and analyzing only the essential data from patient records
Detailed Description:
Liver transplantation stands as the gold standard for treating decompensated chronic liver diseases and select cases of hepatocellular carcinoma Over time post-transplant survival rates have shown consistent improvement attributed to advancements in surgical techniques refined immunosuppressive protocols and enhanced comprehension of post-transplant complications These developments have significantly mitigated the incidence of infectious immunological and neoplastic complications following transplantation
Research indicates post-liver transplant survival rates of approximately 85 at one year 68 at five years and 50 at ten years It is important to note that these statistics are based on patients transplanted in the 1990s whose immunosuppression relied on a combination of cyclosporine azathioprine and corticosteroids
The field of immunosuppression has undergone substantial evolution with an expansion in therapeutic options These include the gradual replacement of Cyclosporine A with Tacrolimus and the introduction of interleukin-2 receptor inhibitors mycophenolate mofetil and mTOR inhibitors These innovations facilitate more adaptable protocols offering improved preservation of renal function and allowing for earlier discontinuation of corticosteroids As a result these new therapeutic options offer immunosuppression that is more tailored to each patient with reduced long-term toxicity
The primary objective of this study is to investigate long-term mortality rates following liver transplantation and to identify the various risk factors contributing to mortality in these patients with a particular focus on the current era of immunosuppression techniques This investigation will be conducted within the framework of a French multicentric cohort study
The results of this study have the potential to enhance our understanding of long-term post-transplant mortality and to more accurately identify risk factors This knowledge could inform the refinement of immunosuppressive treatments and post-transplant patient care protocols The overarching aim of this research is to optimize the management of liver transplant recipients and ultimately prolong their survival
Research indicates post-liver transplant survival rates of approximately 85 at one year 68 at five years and 50 at ten years It is important to note that these statistics are based on patients transplanted in the 1990s whose immunosuppression relied on a combination of cyclosporine azathioprine and corticosteroids
The field of immunosuppression has undergone substantial evolution with an expansion in therapeutic options These include the gradual replacement of Cyclosporine A with Tacrolimus and the introduction of interleukin-2 receptor inhibitors mycophenolate mofetil and mTOR inhibitors These innovations facilitate more adaptable protocols offering improved preservation of renal function and allowing for earlier discontinuation of corticosteroids As a result these new therapeutic options offer immunosuppression that is more tailored to each patient with reduced long-term toxicity
The primary objective of this study is to investigate long-term mortality rates following liver transplantation and to identify the various risk factors contributing to mortality in these patients with a particular focus on the current era of immunosuppression techniques This investigation will be conducted within the framework of a French multicentric cohort study
The results of this study have the potential to enhance our understanding of long-term post-transplant mortality and to more accurately identify risk factors This knowledge could inform the refinement of immunosuppressive treatments and post-transplant patient care protocols The overarching aim of this research is to optimize the management of liver transplant recipients and ultimately prolong their survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None